For cMET inhibitors, the IC50 of campatinib (12 μM) was much higher than tivantinib (1 or 1.2 μM) and crizotinib (0.5 μM) in chondrosarcoma cell lines (Figure 6—figure supplement 1). This evidence concerns the gene MET and chondrosarcoma.